Welcome to Idorsia

Results of the Annual General Meeting 2021

Our 2020 report
consists of four
books

Our key assets have
the potential to
transform treatment in
the target indications...

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.

Idorsia’s success depends on its people.

Idorsia's development compounds target a number of different diseases.

09 Jun 2021	Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021
25 May 2021	European Commission approves Ponvory (ponesimod) for the treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features
12 May 2021	Idorsia holds its Annual General Meeting of Shareholders

Event	When
Half-Year 2021 Financial Results reporting*	July 27, 2021
Nine-months 2021 Financial Results reporting*	October 26, 2021
Full-Year 2021 Financial Results reporting*	February 8, 2022

*We will be in a silent period for 10 days ahead of the financial reporting.

IDIA SIX Swiss Exchange

At 17:19:39 CET

26.02 CHF

-0.08 (-0.31 %)

Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91

4123 Allschwil

Switzerland